Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Relationship Between R and FP Plasmids in Pseudomonas aeruginosa. Pamela L. Royle and Bruce W. Holloway* 293-297


Multiple Changes of Penicillin-Binding Proteins in Penicillin-Resistant Clinical Isolates of Streptococcus pneumoniae. Regine Hakenbeck, Martha Tarpay, and Alexander Tomasz* 364-371

Penicillin-Binding Proteins of Multiply Antibiotic-Resistant South African Strains of Streptococcus pneumoniae. Sonia Zigelboim and Alexander Tomasz* 434-442

Resistance to Adriamycin Cytotoxicity Among Respiratory-Deficient Mutants. Sharon C. Hixon,* Adil Oçak, Jonah E. Thomas, and J. Patrick Daugherty 443-449

Site of Action of Isoniazid on the Electron Transport Chain and Its Relationship to Nicotinamide Adenine Dinucleotide Regulation in Mycobacterium phlei. R. Peter Herman and Morton M. Weber* 450-454

Physiological Effects and Microbial Susceptibility


Incidence of R-Plasmids in Fecal Flora of Healthy Household Dogs. Dwight C. Hirsch,* Gerald V. Ling, and Annette L. Ruby 313-315

Effects of Sulfamethoxazole and Trimethoprim on Human Neutrophil and Lymphocyte Functions In Vitro: In Vivo Effects of Cotrimoxazole. R. Anderson,* Gisela Grabow, Robyn Oosthuizen, Annette Theron, and A. J. Van Rensburg 322-326


Continued on following page

Bactericidal Synergy Between Penicillin or Ampicillin and Amino-glycosides Against Antibiotic-Tolerant Lactobacilli. ARNOLD S. BAYER,* ANTHONY W. CHOW, JOAN O. MORRISON, AND LUCIEN B. GUZE ................................................................. 359–363

Potentially Synergistic Antimicrobial Combinations with Metronidazole Against Bacteroides fragilis. EDWARD D. RALPH* AND YURI E. AMATNIEKS ................................................................. 379–382

Effect of Contamination Levels on Antimicrobial Susceptibilities Tested by Autobac I. AZRA SHAHIDI* AND IRENE CHOY ............. 389–392

Effect of Inoculum Size and β-Lactamase Production on In Vitro Activity of New Cephalosporins Against Haemophilus Species. ROBERT R. BULGER AND JOHN A. WASHINGTON II* ................................................................. 393–396

Comparative In Vitro Activities of Cefotaxime and Ceftizoxime (FK749): New Cephalosporins with Exceptional Potency. DAVID GREENWOOD,* NEIL PEARSON, ADRIAN ELEY, AND FRANCIS O'GRADY ................................................................. 397–401

Comparison of In Vitro Activity of Moxalactam (LY127935) with Cefazolin, Amikacin, Tobramycin, Carbenicillin, Piperacillin, and Ticarcillin Against 420 Blood Culture Isolates. LARRY G. REIMER,* STANLEY MIRRET, AND L. BARTH RELLER ................................................................. 412–416

Bioassay of Antibiotics in Body Fluids from Patients Receiving Cancer Chemotherapeutic Agents. DONALD N. WRIGHT* AND JOHN M. MATSEN ................................................................. 417–422

In Vitro Evaluation of Cefoperazone. ANNE M. HINKLE, BARBARA M. LEBLANC, AND GERALD P. BODEY* ................................................................. 423–427

Effect of Penicillin and Virginiamycin on Drug Resistance in Lactose-Fermenting Enteric Flora. STUART A. GAINE,* LARRY D. ROLLINS, ROBERT D. WILLIAMS, AND MURRAY SELWYN ................................................................. 428–433

Antiviral and Interferon-Inducing Properties of Interferon Inducers Administered with Prostaglandins. DALE A. STRINGFELLOW ................................................................. 455–460


In Vitro Susceptibility of 104 Clinical Isolates of Haemophilus influenzae to Moxalactam (LY127935), Ampicillin, Chloramphenicol, and Ticarcillin. EDWARD O. MASON, JR.,* SHELDON L. KAPLAN, DONALD C. ANDERSON, DAVID B. HINDS, AND RALPH D. FEIGIN ................................................................. 470–473

Activity of Cefotaxime-Aminoglycoside Combinations Against Aminoglycoside-Resistant Pseudomonas. PATRICK R. MURRAY ................................................................. 474–476

Combined Effect of Amphotericin B and Rifampin on Candida Species. JOHN E. EDWARDS, JR.,* JOAN MORRISON, DAVID K. HENDERSON, AND JOHN Z. MONTGOMERIE ................................................................. 484–487

Comparison of Cefoperazone, Cefotaxime, and Moxalactam (LY127935) Against Aerobic Gram-Negative Bacilli. SELWYN D. R. LANG,* DEBORAH J. EDWARDS, AND DAVID T. DURACK ................................................................. 488–493


Continued on following page
Radioimmunoassay of Gentamicin in Micro monospora Medium Extracts. ARIE ROSNER* and HAIM AVIV .......................... 510-511


In Vitro Activities of Cefotaxime and Moxalactam (LY127935) Against Haemophilus influenzae. JAMES H. JORGENSEN,* SHARON A. CRAWFORD, and GARY A. ALEXANDER .................. 516-517

Pharmacology and Therapeutics

In Vitro and In Vivo Antimicrobial Activities of Sporaricin A, a New Aminoglycoside. FUJIO KOBAYASHI,* YUSHI SAINO, TOMOYUKI KOSHI, and YUKIO HATTORI .................. 337-343

Pharmacokinetics of Azlocillin in Subjects with Normal and Impaired Renal Function. A. LEROY,* G. HUMBERT, M. GODIN, and J. P. FILLASTRE ........... 344-349

Effects of Tetracycline on the Streptococcal Flora of Periodontal Pockets. ROBERT J. HAWLEY, LINDA N. LEE, and DONALD J. LEBLANC* .................. 372-378

Intrarenal Distribution of Trimethoprim and Sulfamethoxazole. SYLVIE TROTTIER, MICHEL G. BERGERON,* and CELINE LESSARD ...................... 383-388

Randomized Trial of High- and Low-Dose Ampicillin Therapy for Treatment of Severe Dysentery Due to Shigella dysenteriae Type 1. R. H. GILMAN,* F. KOSTER, S. ISLAM, J. MCLAUGHLIN, and M. M. RAHAMAN .................. 402-405

Pharmacokinetics and Bacteriological Efficacy of Moxalactam (LY127935), Netilmicin, and Ampicillin in Experimental Gram-Negative Enteric Bacillary Meningitis. URS B. SCHAAD, GEORGE H. MCCracken, JR.,* CHRISTINE A. LOOCK, and MARION L. THOMAS ................ 406-411

Synergistic Action of Ampicillin and Nafcilbin Against Ampicillin-Resistant Haemophilus influenzae. RAM YOGEV,* ERNEST BURKOLDER, and A TODD DAVIS .................. 461-463

Isolation of Drug-Resistant Aeromonas hydrophila from Aquatic Environments. LORE ANN McNICOL, K. M. S. AZIZ, IMDADUL HUQ, JAMES B. KAPER, HANK A. LOCKMAN, ELAINE F. REMMERS, WILLIAM M. SPIRA, MARY J. VOLI, and RITA R. COLWELL* .................. 477-483

Experimental Respiratory Tract Infection with Klebsiella pneumoniae DT-S in Mice: Chemotherapy with Kanamycin. TAKESHI NISHI and KANJI TSUCHIYA* .................. 494-505

* Asterisk refers to person to whom inquiries regarding the paper should be addressed.